Clearmind Medicine Inc.
CMNDHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeClearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company carries a $2.4M market cap, placing it firmly in the micro-cap category. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Market Cap
$2.4M
Beta
-1.19
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-154.58
EPS (Fwd)
—
ROE
-114.6%
ROA
-51.4%
Cash
$13.6M
Total Debt
$85,588
Free CF
-$3.5M
52W Change
-99.6%
Annual Financials
Cash vs Debt
Where CMND stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CMND finished 84.41% below its 150-day moving average ($12.38) and 97.55% below its 200-day moving average ($78.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMND overbought or oversold?
At the July 15, 2026 close, CMND's RSI(14) was 11.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Clearmind Medicine Inc. holds $13.6M in cash against $86K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$3.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -114.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
CMND's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CMND has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CMND's risk profile alongside its fundamentals and technical indicators provides a more complete picture.